Testing drug sensitivity in micro tumors to guide treatment for colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of a 3D drug sensitivity test on micro tumors (PTC) in guiding postoperative adjuvant treatment strategies for colorectal cancer. Patients aged 18 to 75 with colorectal cancer will be randomly assigned to either a PTC drug sensitivity test group or a control group that follows standard clinical practices. The study will compare clinical outcomes between the two groups, focusing on disease-free survival rates over three years. The goal is to provide real-world data supporting the use of this technology for personalized treatment approaches in colorectal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 \~ 75 years old, regardless of gender
* Patients with colorectal cancer diagnosed by histopathology or cytology
* Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
* Having at least one assessable tumor focus
* ECoG physical condition score ≤ 2 points
* Voluntarily participate and sign informed consent

Exclusion Criteria:

* Patients diagnosed with metastasis
* Patients who cannot obtain tumor samples
* Pregnant and lactating women
* Patients with poor compliance
* Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment
* Patients with other malignant tumors
* Suffering from serious mental and nervous system diseases
* The researchers believe that patients should not be selected for this study

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Guole Lin
• Email: linguole@126.com
• Phone: 13801081483

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Quality of life after colorectal cancer treatment

  This project will test whether late side effects at 6, 12, and 24 months affect quality of life in people aged 25–65 who completed initial treatment for colorectal cancer at the Institute of Oncology Ljubljana.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07427901

• CEA-targeted CAR-T for advanced CEA-positive solid tumors

  This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui · NCT07179692

• Preserving the superior left colic artery to improve blood flow to the descending colon before reconnecting the bowel after left-sided, rectal, or ovarian cancer surgery

  This trial will test in adults having left colon, rectal, or ovarian cancer surgery whether preserving the superior left colic artery and temporarily managing the inferior mesenteric artery improves blood flow to the descending colon and reduces healing problems after the bowel is reconnected.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier, Herault · NCT07098182

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

  This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.

  Recruiting at 14 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 13 other locations · NCT07011576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.